Filament Health Corp (FLHLF)

$0.00 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 10,000
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company's leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provides in-house human clinical trials, as well as license technology to drug developers, researchers, and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Address:
4475 Wayburne Drive, Unit 210, Burnaby, Canada
MurseOMoney
MurseOMoney May. 11 at 1:56 AM
$CMPS $TRUFF $FLHLF Just piggybacking off @Waldo_5150 to share some interesting info:
0 · Reply
MurseOMoney
MurseOMoney May. 10 at 6:53 AM
$CMPS Feel free to shun me off the boards, but just here to chime in for support of psilocybin candidates as a whole 🤗: $TRUFF +$FLHLF are still have the only naturally derived psilocybin candidate, with 50-70 clinical sites utilizing it, as well as multiple phase 2 studies running concurrently across 14+ indications. They are no Compass, and I want Compass to succeed ENORMOUSLY, but when ppl start understanding how truly hard it is to standardize and get approval for treatment from botanical sources, they’ll see the light. Also blowing past multiple phase 2 studies may help in this regard. Their extraction patents are gold standard and it’ll be hard for any company to match their reputation in the world of botanically grown. Ultimately, it’s a whole lot cheaper to grow in the field than in the lab, and they’re currently building an 85K sqr foot facility for shroom harvest 🍄 My bet is on Compass for blaring reasons, but don’t sleep on $TRUFF & $FLHLF 🚀
1 · Reply
WildDeuces
WildDeuces May. 6 at 4:56 PM
$FLHLF sold
0 · Reply
prismmarketview
prismmarketview Mar. 16 at 2:43 PM
Magdalena Biosciences, the joint venture between Jaguar Health ( $JAGX) and Filament Health ( $FLHLF), has started a one‑month mouse study in Alberta testing a whole‑leaf coca extract as an appetite suppressant aimed at helping people maintain weight loss after GLP‑1 obesity drugs, marking its first obesity‑focused program on top of its broader plant‑based CNS pipeline. https://prismmarketview.com/magdalena-biosciences-the-jaguar-health-filament-health-jv-has-begun-preclinical-tests-of-coca-based-appetite-suppressants/
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Mar. 11 at 5:57 PM
Red Light Holland Expands Its Psilocybin Strategy: https://substack.com/home/post/p-190567447 $FLHLF $TRUFF
0 · Reply
JenniferCanada
JenniferCanada Feb. 9 at 12:04 PM
$JAGX is Magdalena more owned by jagx or filament? Is this likely to be a profitable side venture? Any info and opinions are appreciated! $FLHLF
1 · Reply
JenniferCanada
JenniferCanada Jan. 2 at 7:27 PM
$FLHLF I'm surprised this stock has so few followers. I wonder what might increase watchers? I would think the $JAGX crew would be at least low key interested considering the joint venture (Magdalena). Curious. 🤷🏻‍♀️
0 · Reply
GodReignsSupreme
GodReignsSupreme Dec. 19 at 5:02 AM
$FLHLF Research interest in the potential of psychedelic drugs to treat mental health conditions including depression, anxiety, existential distress in serious medical illnesses, post-traumatic stress disorder, and addiction has been growing. The U.S. Food and Drug Administration (FDA) granted “breakthrough therapy” designation to psilocybin-assisted psychotherapy for both major depressive disorder in 2019 and treatment-resistant depression in 2018. The FDA may also grant this designation for treatments for serious or life-threatening conditions where preliminary evidence suggests the treatment may improve the conditions substantially more than other available options.
0 · Reply
GodReignsSupreme
GodReignsSupreme Dec. 19 at 4:56 AM
$FLHLF Psychedelics are stepping out of the shadows and into the spotlight as some of the most promising tools in modern wellness and mental health. Once associated with the counterculture of the 1960s, these substances are now being rigorously studied for their potential to treat a range of mental health conditions, from depression to PTSD. The future of psychedelics is no longer a fringe idea—it’s becoming a mainstream reality with significant implications for how we approach mental well-being
0 · Reply
YoctoYotta
YoctoYotta Sep. 9 at 1:04 PM
$FLHLF these stock are currently extremely undervalued. When the market change they will get better. Read due diligance for the stock. And decide what you think. Phase 2 and 3 is always better for short term Performance.
1 · Reply
Latest News on FLHLF
No data available.
MurseOMoney
MurseOMoney May. 11 at 1:56 AM
$CMPS $TRUFF $FLHLF Just piggybacking off @Waldo_5150 to share some interesting info:
0 · Reply
MurseOMoney
MurseOMoney May. 10 at 6:53 AM
$CMPS Feel free to shun me off the boards, but just here to chime in for support of psilocybin candidates as a whole 🤗: $TRUFF +$FLHLF are still have the only naturally derived psilocybin candidate, with 50-70 clinical sites utilizing it, as well as multiple phase 2 studies running concurrently across 14+ indications. They are no Compass, and I want Compass to succeed ENORMOUSLY, but when ppl start understanding how truly hard it is to standardize and get approval for treatment from botanical sources, they’ll see the light. Also blowing past multiple phase 2 studies may help in this regard. Their extraction patents are gold standard and it’ll be hard for any company to match their reputation in the world of botanically grown. Ultimately, it’s a whole lot cheaper to grow in the field than in the lab, and they’re currently building an 85K sqr foot facility for shroom harvest 🍄 My bet is on Compass for blaring reasons, but don’t sleep on $TRUFF & $FLHLF 🚀
1 · Reply
WildDeuces
WildDeuces May. 6 at 4:56 PM
$FLHLF sold
0 · Reply
prismmarketview
prismmarketview Mar. 16 at 2:43 PM
Magdalena Biosciences, the joint venture between Jaguar Health ( $JAGX) and Filament Health ( $FLHLF), has started a one‑month mouse study in Alberta testing a whole‑leaf coca extract as an appetite suppressant aimed at helping people maintain weight loss after GLP‑1 obesity drugs, marking its first obesity‑focused program on top of its broader plant‑based CNS pipeline. https://prismmarketview.com/magdalena-biosciences-the-jaguar-health-filament-health-jv-has-begun-preclinical-tests-of-coca-based-appetite-suppressants/
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Mar. 11 at 5:57 PM
Red Light Holland Expands Its Psilocybin Strategy: https://substack.com/home/post/p-190567447 $FLHLF $TRUFF
0 · Reply
JenniferCanada
JenniferCanada Feb. 9 at 12:04 PM
$JAGX is Magdalena more owned by jagx or filament? Is this likely to be a profitable side venture? Any info and opinions are appreciated! $FLHLF
1 · Reply
JenniferCanada
JenniferCanada Jan. 2 at 7:27 PM
$FLHLF I'm surprised this stock has so few followers. I wonder what might increase watchers? I would think the $JAGX crew would be at least low key interested considering the joint venture (Magdalena). Curious. 🤷🏻‍♀️
0 · Reply
GodReignsSupreme
GodReignsSupreme Dec. 19 at 5:02 AM
$FLHLF Research interest in the potential of psychedelic drugs to treat mental health conditions including depression, anxiety, existential distress in serious medical illnesses, post-traumatic stress disorder, and addiction has been growing. The U.S. Food and Drug Administration (FDA) granted “breakthrough therapy” designation to psilocybin-assisted psychotherapy for both major depressive disorder in 2019 and treatment-resistant depression in 2018. The FDA may also grant this designation for treatments for serious or life-threatening conditions where preliminary evidence suggests the treatment may improve the conditions substantially more than other available options.
0 · Reply
GodReignsSupreme
GodReignsSupreme Dec. 19 at 4:56 AM
$FLHLF Psychedelics are stepping out of the shadows and into the spotlight as some of the most promising tools in modern wellness and mental health. Once associated with the counterculture of the 1960s, these substances are now being rigorously studied for their potential to treat a range of mental health conditions, from depression to PTSD. The future of psychedelics is no longer a fringe idea—it’s becoming a mainstream reality with significant implications for how we approach mental well-being
0 · Reply
YoctoYotta
YoctoYotta Sep. 9 at 1:04 PM
$FLHLF these stock are currently extremely undervalued. When the market change they will get better. Read due diligance for the stock. And decide what you think. Phase 2 and 3 is always better for short term Performance.
1 · Reply
JenniferCanada
JenniferCanada Sep. 7 at 11:23 AM
$FLHLF I'm really curious about this stock. Im confused why there are only 36 watchers compared to $JAGX with 80,000+. Especially since the two companies are affiliated through one shared company. Can anyone help me better understand the profile and potential trajectory for Filament? Any upcoming catalysts? I see a lot of news around approved patents worldwide.
1 · Reply
JenniferCanada
JenniferCanada Jul. 14 at 9:24 PM
$FLHLF Hi all. The price on my app is showing different than this site .. 0.05 vs 0.03. Can anyone explain this? Possibly USD vs CAD? I'm tagging $JAGX friends to try and help me understand?
1 · Reply
newsfile_corp
newsfile_corp Jun. 15 at 1:57 AM
https://nfne.ws/213194 $FLHLF #OTC #OTCMarkets #OTCStocks #banking #financialservices #Investing
0 · Reply
ballerallday
ballerallday May. 28 at 7:51 PM
$GME Will remain between $30 and $15 for a long time. Sell calls and puts. While you are waiting, check out this penny stock with huge potential $FLHLF
0 · Reply
Bobjd445
Bobjd445 Feb. 25 at 6:58 PM
$FLHLF psilocybin is making more news in recent times. My state IN just made it legal to do medical research with it. That says something, we haven’t even legalized marijuana yet.
0 · Reply
newsfile_corp
newsfile_corp Nov. 8 at 8:27 PM
https://nfne.ws/186698 $FLHLF #Banking #FinancialServices #Investing #OTC #OTCMarkets #OTCStocks
0 · Reply
Stock_Titan
Stock_Titan Nov. 8 at 8:20 PM
$FLHLF Filament Health Announces Annual General Meeting Voting Results https://www.stocktitan.net/news/FLHLF/filament-health-announces-annual-general-meeting-voting-emtvz0u6odyg.html
0 · Reply
YoctoYotta
YoctoYotta Oct. 7 at 1:51 PM
$FLHLF https://news.spacconference.com/2023/10/02/jupiter-acquisition-files-investor-presentation-on-filament-health-deal/
0 · Reply
swingingtech
swingingtech Sep. 21 at 11:17 PM
$JAGX $FLHLF https://wallstreetwaves.com/perus-coca-leaf-will-be-used-for-research-toward-treating-adhd-learn-the-details/
0 · Reply